Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access
by-
eBook
9781440861901
MLA
Maschke, Karen and Gusmano, Michael. Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access. Praeger, 2018. ABC-CLIO, publisher.abc-clio.com/9781440861901.
Chicago Manual of Style
Maschke, Karen, and Michael Gusmano. Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access. Praeger, 2018. http://publisher.abc-clio.com/9781440861901
APA
Maschke, K. & Gusmano, M. (2018). Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access. Retrieved from http://publisher.abc-clio.com/9781440861901
- Description
-
This book analyzes policy fights about what counts as good evidence of safety and effectiveness when it comes to new health care technologies in the United States and what political decisions mean for patients and doctors.
• Helps readers to understand the political, economic, and ideological dimensions of disputes about health technology assessment and the implications of various policy approaches for patients and the health care system• Includes discussion of disputes related to hot topics such as stem cell therapies, mammography screening, genomic tests, breast cancer drugs, and Hepatitis C medications
• Discusses interest group pressure on government from large pharmaceutical companies and medical device manufacturers
• Connects to current political rhetoric about speeding up the availability of technology
- Table of Contents
-
Table of Contents
Debating Modern Medical Technologies: The Politics of Safety, Effectiveness, and Patient Access
Author(s): Maschke, Karen; Gusmano, Michael;Contributors: Maschke, Karen; Gusmano, Michael;Abstract:This book analyzes policy fights about what counts as good evidence of safety and effectiveness when it comes to new health care technologies in the United States and what political decisions mean for patients and doctors.
• Helps readers to understand the political, economic, and ideological dimensions of disputes about health technology assessment and the implications of various policy approaches for patients and the health care system• Includes discussion of disputes related to hot topics such as stem cell therapies, mammography screening, genomic tests, breast cancer drugs, and Hepatitis C medications
• Discusses interest group pressure on government from large pharmaceutical companies and medical device manufacturers
• Connects to current political rhetoric about speeding up the availability of technology
SortTitle: debating modern medical technologies: the politics of safety, effectiveness, and patient accessAuthor Info:Karen J. MaschkeauthorMichael K. GusmanoauthoreISBN-13: 9781440861901Cover Image URL: ~~FreeAttachments/9781440861901.jpgPrint ISBN-13: 9781440861895Imprint: PraegerPages: 232Publication Date: 20180930- Cover Cover11
- Title iii4
- Copyright iv5
- Contents v6
- Acknowledgments vii8
- Chapter 1: Evidence, Politics, and Medical Care Technology 110
- Chapter 2: Evolving Public- and Private-Payer Approaches to Evidence and Health Technology Assessment 1322
- Evidence and the Influence of Scientific Medicine 1423
- From Cost Crisis to Value for Money 1625
- Expanding the Federal Government’s Role in Health Technology Assessment 1928
- Political Attacks on Health Services Research 2130
- Renewed Enthusiasm for Comparative Effectiveness Research 2332
- Medicare’s Renewed Interest in Evidence of Effectiveness 2635
- Evidence of Value for Private Payers 2837
- Conclusion 2938
- Chapter 3: Mammography Screening: Vested Interests and Polarization 3039
- Breast Cancer Trends in the United States 3140
- Breast Cancer Advocacy and the Role of Mammography Screening 3241
- Mammography Screening 3544
- Concerns About Underuse and Overuse of Screening 3645
- The 2009 Mammography Screening Recommendations 4049
- The Problem with Disinvestment 4251
- Mammography and the Limited Focus of Breast Cancer Advocacy 4352
- The Limits and Politics of Weighting Risks 4453
- Obamacare, Rationing, and Hyperpartisanship 4554
- Conclusion 4655
- Chapter 4: When Medicare Said No for Amyloid PET Imaging 4857
- Chapter 5: Placing a Value on Cure: Lessons from the New Generation of Hepatitis C Drugs 6372
- Chapter 6: Avastin and the Politics of Accelerated Approval 8089
- Chapter 7: The Path to the Clinic for Stem Cell and Other Regenerative Medicine Interventions 99108
- Chapter 8: Conclusion: The 21st Century Cures Act and the Future of Health Technology Assessment 118127
- Notes 135144
- Bibliography 177186
- Index 211220
- About the Authors 217226